Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Relay Therapeutics (Nasdaq: RLAY) will report first quarter 2026 financial results and corporate highlights on Tuesday, May 5, 2026 after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) will report first quarter 2026 financial results and corporate highlights on Tuesday, May 5, 2026 after U.S. market close. The company is a clinical-stage small molecule precision medicine firm focused on oncology and genetic-disease therapies.
Details
News Market Reaction – RLAY
On Apr 30, the first trading day after this news, RLAY closed 3.10% above the previous close.
Data tracked by StockTitan Argus for the Apr 30 session.
Key Figures
- Earnings release date
- May 5, 2026
- Scheduled report of Q1 2026 financial results after U.S. market close
Previous Earnings date Reports
-
Set timing to release Q4 and full-year 2025 financial results and highlights.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
precision medicine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report first quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Tuesday, May 5, 2026.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.